Can domestic formulations shield Indian pharma from US pricing pressure in Q3?

January 16, 2026

Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.

More To Explore

M-cap of 6 of top-10 most valued firms surges Rs 1 lakh cr; Airtel, Bajaj Fin top winners

In the last week, Indian stock markets thrived, witnessing a remarkable Rs 1 lakh crore increase in the combined market valuation of six leading companies.

July 5, 2026

11 largecap stocks with upside potential of up to 50%. Do you own any?

Indian investors are eyeing significant gains as analyst forecasts highlight 11 largecap BSE stocks poised for 25% to 50% growth in the next year. Companies

July 5, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003